{"id":"https://openalex.org/W2245961990","doi":"https://doi.org/10.1200/jco.1998.16.7.2321","title":"Cellular pharmacodynamics and plasma pharmacokinetics of parenterally infused hydroxyurea during a phase I clinical trial in chronic myelogenous leukemia.","display_name":"Cellular pharmacodynamics and plasma pharmacokinetics of parenterally infused hydroxyurea during a phase I clinical trial in chronic myelogenous leukemia.","publication_year":1998,"publication_date":"1998-07-01","ids":{"openalex":"https://openalex.org/W2245961990","doi":"https://doi.org/10.1200/jco.1998.16.7.2321","mag":"2245961990","pmid":"https://pubmed.ncbi.nlm.nih.gov/9667246"},"language":"en","primary_location":{"id":"doi:10.1200/jco.1998.16.7.2321","doi":"https://doi.org/10.1200/jco.1998.16.7.2321","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.1998.16.7.2321","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5024454882","display_name":"Varsha V. Gandhi","orcid":"https://orcid.org/0000-0002-3172-9166","observed_orcids":["https://orcid.org/0000-0002-3172-9166"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"V Gandhi","raw_affiliation_strings":["Department of Clinical Investigation, The University of Texas M.D. Anderson Cancer Center, Houston 77030, USA. vgandhi@notes.mdacc.tmc.edu","Experimental Therapeutics"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Clinical Investigation, The University of Texas M.D. Anderson Cancer Center, Houston 77030, USA. vgandhi@notes.mdacc.tmc.edu","institution_ids":["https://openalex.org/I1343551460"]},{"raw_affiliation_string":"Experimental Therapeutics","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5036290225","display_name":"William K. Plunkett","orcid":"https://orcid.org/0000-0001-9311-2164","observed_orcids":["https://orcid.org/0000-0001-9311-2164"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"W Plunkett","raw_affiliation_strings":["Experimental Therapeutics"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Experimental Therapeutics","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5090435894","display_name":"Hagop M. Kantarjian","orcid":"https://orcid.org/0000-0002-1908-3307","observed_orcids":["https://orcid.org/0000-0002-1908-3307"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"H Kantarjian","raw_affiliation_strings":["UNIVERSITY OF TEXAS M.D. ANDERSON CANCER CENTER"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"UNIVERSITY OF TEXAS M.D. ANDERSON CANCER CENTER","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5011529063","display_name":"Moshe Talpaz","orcid":"https://orcid.org/0000-0003-3361-3981","observed_orcids":["https://orcid.org/0000-0003-3361-3981"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"M Talpaz","raw_affiliation_strings":["UNIVERSITY OF TEXAS M.D. ANDERSON CANCER CENTER"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"UNIVERSITY OF TEXAS M.D. ANDERSON CANCER CENTER","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5112192765","display_name":"L. E. Robertson","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"L E Robertson","raw_affiliation_strings":["UNIVERSITY OF TEXAS M.D. ANDERSON CANCER CENTER"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"UNIVERSITY OF TEXAS M.D. ANDERSON CANCER CENTER","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5102743501","display_name":"Susan Mary O'Brien","orcid":"https://orcid.org/0000-0003-3386-6540","observed_orcids":["https://orcid.org/0000-0003-3386-6540"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"S O'Brien","raw_affiliation_strings":["UNIVERSITY OF TEXAS M.D. ANDERSON CANCER CENTER"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"UNIVERSITY OF TEXAS M.D. ANDERSON CANCER CENTER","institution_ids":["https://openalex.org/I1343551460"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":0.398,"has_fulltext":false,"cited_by_count":33,"citation_normalized_percentile":{"value":0.63007464,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":96},"biblio":{"volume":"16","issue":"7","first_page":"2321","last_page":"2331"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11215","display_name":"Chronic Myeloid Leukemia Treatments","score":0.9458000063896179,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11215","display_name":"Chronic Myeloid Leukemia Treatments","score":0.9458000063896179,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11157","display_name":"Chronic Lymphocytic Leukemia Research","score":0.017799999564886093,"subfield":{"id":"https://openalex.org/subfields/2716","display_name":"Genetics"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11845","display_name":"Cancer therapeutics and mechanisms","score":0.011800000444054604,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/hydroxyurea","display_name":"hydroxyurea","score":1.0},{"id":"https://openalex.org/keywords/chronic-myeloid-leukemia","display_name":"chronic myeloid leukemia","score":0.9990000128746033},{"id":"https://openalex.org/keywords/pharmacodynamics","display_name":"pharmacodynamics","score":0.6029999852180481},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.9480000138282776},{"id":"https://openalex.org/keywords/maximum-tolerated-dose","display_name":"maximum tolerated dose","score":0.7710000276565552},{"id":"https://openalex.org/keywords/ribonucleotide-reductase-inhibition","display_name":"ribonucleotide reductase inhibition","score":0.8360000252723694},{"id":"https://openalex.org/keywords/datp","display_name":"dATP","score":0.7940000295639038},{"id":"https://openalex.org/keywords/dna-synthesis-inhibition","display_name":"DNA synthesis inhibition","score":0.9959999918937683},{"id":"https://openalex.org/keywords/myelosuppression","display_name":"myelosuppression","score":0.902999997138977},{"id":"https://openalex.org/keywords/mucositis","display_name":"mucositis","score":0.9810000061988831},{"id":"https://openalex.org/keywords/continuous-intravenous-infusion","display_name":"continuous intravenous infusion","score":0.765999972820282},{"id":"https://openalex.org/keywords/leukemic-blasts","display_name":"leukemic blasts","score":0.4309999942779541}],"concepts":[{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.6874857544898987},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.6860702037811279},{"id":"https://openalex.org/C2778496288","wikidata":"https://www.wikidata.org/wiki/Q6931269","display_name":"Mucositis","level":3,"score":0.6620805859565735},{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.650897741317749},{"id":"https://openalex.org/C2776960273","wikidata":"https://www.wikidata.org/wiki/Q729735","display_name":"Chronic myelogenous leukemia","level":3,"score":0.5815247297286987},{"id":"https://openalex.org/C111113717","wikidata":"https://www.wikidata.org/wiki/Q725307","display_name":"Pharmacodynamics","level":3,"score":0.5545472502708435},{"id":"https://openalex.org/C2779316324","wikidata":"https://www.wikidata.org/wiki/Q212272","display_name":"Hydroxycarbamide","level":3,"score":0.4422953724861145},{"id":"https://openalex.org/C2778461978","wikidata":"https://www.wikidata.org/wiki/Q29496","display_name":"Leukemia","level":2,"score":0.4343884289264679},{"id":"https://openalex.org/C2780873365","wikidata":"https://www.wikidata.org/wiki/Q496812","display_name":"Leukopenia","level":3,"score":0.4227748215198517},{"id":"https://openalex.org/C29730261","wikidata":"https://www.wikidata.org/wiki/Q274160","display_name":"Toxicity","level":2,"score":0.35572177171707153},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.29675358533859253},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.22052040696144104}],"mesh":[{"descriptor_ui":"D000255","descriptor_name":"Adenosine Triphosphate","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":false},{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000368","descriptor_name":"Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":true},{"descriptor_ui":"D004305","descriptor_name":"Dose-Response Relationship, Drug","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006918","descriptor_name":"Hydroxyurea","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D006918","descriptor_name":"Hydroxyurea","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":false},{"descriptor_ui":"D006918","descriptor_name":"Hydroxyurea","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":true},{"descriptor_ui":"D007262","descriptor_name":"Infusions, Intravenous","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008452","descriptor_name":"Maximum Allowable Concentration","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D015464","descriptor_name":"Leukemia, Myelogenous, Chronic, BCR-ABL Positive","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":true},{"descriptor_ui":"D015464","descriptor_name":"Leukemia, Myelogenous, Chronic, BCR-ABL Positive","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true}],"locations_count":2,"locations":[{"id":"doi:10.1200/jco.1998.16.7.2321","doi":"https://doi.org/10.1200/jco.1998.16.7.2321","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.1998.16.7.2321","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},{"id":"pmid:9667246","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/9667246","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","raw_type":"Clinical Trial"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","score":0.9922999739646912,"id":"https://metadata.un.org/sdg/3"}],"sustainable_development_goals_aurora":[{"display_name":"Good health and well-being","score":0.6399999856948853,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[{"display_name":"Clinical Trial","id":"https://openalex.org/study-designs/clinical-trial"}],"awards":[{"id":"https://openalex.org/G1042671589","display_name":null,"funder_award_id":"CA 32839","funder_id":"https://openalex.org/F4320337351","funder_display_name":"National Cancer Institute"},{"id":"https://openalex.org/G1303459896","display_name":"Biochemical Strategies to Increase Leukemia Response","funder_award_id":"R01CA057629","funder_id":"https://openalex.org/F4320337351","funder_display_name":"National Cancer Institute"},{"id":"https://openalex.org/G1983633267","display_name":null,"funder_award_id":"CA57629","funder_id":"https://openalex.org/F4320337351","funder_display_name":"National Cancer Institute"},{"id":"https://openalex.org/G2556538672","display_name":"Cellular Pharmacology in Cancer Chemotherapy","funder_award_id":"R01CA032839","funder_id":"https://openalex.org/F4320337351","funder_display_name":"National Cancer Institute"}],"funders":[{"id":"https://openalex.org/F4320337351","display_name":"National Cancer Institute","ror":"https://ror.org/040gcmg81"}],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":49,"referenced_works":["https://openalex.org/W1171060","https://openalex.org/W76119661","https://openalex.org/W138942642","https://openalex.org/W165992214","https://openalex.org/W1540991620","https://openalex.org/W1544879211","https://openalex.org/W1795204252","https://openalex.org/W1803924298","https://openalex.org/W1819781110","https://openalex.org/W1943398151","https://openalex.org/W1965819376","https://openalex.org/W1992193524","https://openalex.org/W1994701391","https://openalex.org/W1997564325","https://openalex.org/W2002534840","https://openalex.org/W2011960809","https://openalex.org/W2016243747","https://openalex.org/W2016835142","https://openalex.org/W2020375927","https://openalex.org/W2023282013","https://openalex.org/W2030405093","https://openalex.org/W2040336799","https://openalex.org/W2043211166","https://openalex.org/W2044241739","https://openalex.org/W2048458737","https://openalex.org/W2048956687","https://openalex.org/W2050697291","https://openalex.org/W2072089033","https://openalex.org/W2074318459","https://openalex.org/W2075069452","https://openalex.org/W2081578765","https://openalex.org/W2092089811","https://openalex.org/W2113139348","https://openalex.org/W2138132734","https://openalex.org/W2160850143","https://openalex.org/W2178778111","https://openalex.org/W2223491116","https://openalex.org/W2272344501","https://openalex.org/W2288894655","https://openalex.org/W2291919408","https://openalex.org/W2297609847","https://openalex.org/W2300371971","https://openalex.org/W2320032845","https://openalex.org/W2335320223","https://openalex.org/W2397250210","https://openalex.org/W2411402385","https://openalex.org/W2411631680","https://openalex.org/W2415213076","https://openalex.org/W2466165312"],"related_works":["https://openalex.org/W2016243747","https://openalex.org/W2414952274","https://openalex.org/W3026751728","https://openalex.org/W2094990777","https://openalex.org/W2089229032","https://openalex.org/W1996619882","https://openalex.org/W1992193524","https://openalex.org/W1980512638","https://openalex.org/W1989451442","https://openalex.org/W2272344501"],"abstract_inverted_index":{"PURPOSE:":[0],"To":[1,90],"determine":[2,91],"the":[3,39,92,103,159,177,186,215,244,266,274],"maximum-tolerated":[4],"dose":[5],"(MTD),":[6],"toxicities,":[7],"and":[8,34,44,60,114,173,199],"antileukemic":[9],"activity":[10],"of":[11,46,83,94,127,164,208,218,225,239,246,255,268],"hydroxyurea":[12],"(HU)":[13],"administered":[14,64],"intravenously":[15,65],"to":[16,27,35,71,155,176,214],"patients":[17],"with":[18,74,111,149,243,262],"advanced-phase":[19,234],"chronic":[20],"myelogenous":[21],"leukemia":[22,104],"(CML).":[23],"Further":[24],"objectives":[25],"were":[26,85,106,109,202],"analyze":[28],"pharmacodynamic":[29,253],"effect":[30],"on":[31],"deoxynucleotides":[32],"(dNTPs)":[33],"seek":[36],"relationships":[37],"between":[38],"decrease":[40,184,238],"in":[41,49,76,87,96,102,166,185,191,228,233,249,276],"dNTP":[42,100],"pools":[43,101],"inhibition":[45,117,211,245],"DNA":[47,115,209,247],"synthesis":[48,116,210,248],"CML":[50,75,250],"blasts.":[51,193,251],"PATIENTS":[52],"AND":[53],"METHODS:":[54],"HU":[55,84,95,128,165,226,256],"(8,":[56],"12,":[57],"18,":[58],"27,":[59],"40":[61],"g/m2)":[62],"was":[63,134,140,143,168,174,180,212],"by":[66,121,170,273],"a":[67,131,144,181,258],"24-hour":[68,132,223],"continuous":[69],"infusion":[70,133,224],"19":[72],"adults":[73],"blastic":[77],"or":[78],"accelerated":[79],"phase.":[80],"Plasma":[81],"levels":[82],"analyzed":[86],"all":[88],"patients.":[89],"role":[93],"inhibiting":[97],"ribonucleotide":[98],"reductase,":[99],"cells":[105],"quantitated.":[107],"Correlations":[108],"sought":[110],"these":[112],"parameters":[113],"measured":[118],"ex":[119],"vivo":[120],"[3H]thymidine":[122],"incorporation.":[123],"RESULTS:":[124],"The":[125,137,161,206,236],"MTD":[126],"given":[129],"as":[130],"27":[135],"g/m2.":[136],"dose-limiting":[138],"toxicity":[139],"mucositis.":[141],"There":[142,179],"significant":[145,229],"but":[146,230],"transient":[147,231],"myelosuppression,":[148],"nadir":[150],"counts":[151],"generally":[152],"seen":[153],"3":[154],"4":[156],"days":[157],"after":[158],"dose.":[160,178],"steady-state":[162],"concentration":[163],"plasma":[167],"achieved":[169],"6":[171],"hours,":[172],"proportional":[175],"median":[182],"57%":[183],"deoxyadenosine":[187],"triphosphate":[188,197],"(dATP)":[189],"pool":[190],"circulating":[192],"In":[194],"contrast,":[195],"deoxyguanosine":[196],"(dGTP)":[198],"pyrimidine":[200],"dNTPs":[201],"not":[203],"significantly":[204],"affected.":[205],"extent":[207],"related":[213],"residual":[216],"concentrations":[217],"intracellular":[219,240],"dATP.":[220],"CONCLUSION:":[221],"A":[222],"results":[227],"myelosuppression":[232],"CML.":[235],"specific":[237],"dATP":[241,277],"correlated":[242],"This":[252],"action":[254],"provides":[257],"rationale":[259],"for":[260],"combination":[261],"other":[263],"chemotherapeutic":[264],"agents,":[265],"effects":[267],"which":[269],"could":[270],"be":[271],"augmented":[272],"decline":[275],"pools.":[278]},"counts_by_year":[{"year":2025,"cited_by_count":1},{"year":2024,"cited_by_count":1},{"year":2022,"cited_by_count":2},{"year":2020,"cited_by_count":1},{"year":2019,"cited_by_count":1},{"year":2018,"cited_by_count":1},{"year":2017,"cited_by_count":2},{"year":2016,"cited_by_count":1},{"year":2013,"cited_by_count":1}],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2016-06-24T00:00:00"}